Recombinant Human Anti-CD64 x Human Anti-GD2 Bispecific Antibody (scIgG) (SCIGG-H300)

Recombinant Anti-CD64 x Anti-GD2 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD64 and anti-GD2 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD64 & GD2

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD64 x Human Anti-GD2 Bispecific Antibody (scIgG) (SCIGG-H300). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD64 x Human Anti-GD2 Bispecific Antibody (scIgG) (CAT#: SCIGG-H300)

Specifications

Targets

Customer Reviews and Q&As